WE DEVELOP AN ANTI-INFLAMMATORY DRUG WITH FIRST-IN-CLASS POTENTIAL
We aim to eliminate or alleviate painful symptoms for millions of patients suffering from chronic inflammatory diseases. Lipum has a biological anti-inflammatory drug candidate developed against Rheumatoid Arthritis (RA) – an autoimmune disease characterized by chronic inflammation of the joints. It often causes disability and lowers the quality of life for millions.
Treatment of other chronic inflammatory conditions is also explored. Related diseases are such as Crohn’s disease, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis.
Our biological anti-inflammatory drug candidate provides a novel mechanism of action. Therefore, it is assumed to have less adverse effects than current treatments in use.
Redeye Autoimmune & Inflammatory Disease Event
Watch Einar Ponténs presentation at the Redeye Autoimmune & Inflammatory Disease Event in front of 15 professional investors in person and online audience extended to 869 viewers.